· Earnings watch · CRSP
Crispr Therapeutics AG (CRSP) rebounds 3.1% before Aug. 3 earnings, but trend stays inactive
The gene-editing biotech reports with medium-term performance still under pressure and volume running below its 13-week average.
Crispr Therapeutics AG (CRSP) closed at 47.99 USD in the latest weekly market data before its scheduled Aug. 3 earnings report for the fiscal period ended June 30. The stock’s four-week return is -20.1%, and its twelve-week return is -12.5%.
Confirming evidence is mixed: Market Dynamics shows pressure at -0.27, while Relative Strength stands at -20.1. Latest volume was 7.73 million shares, equal to 0.94x the 13-week average, and the chart is a weekly price path over 52 weeks rather than live intraday action.